Setting Standards Empowering Research Building Shareholder Value First Quarter 2025 Financial Results May 6th 2025 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing the words "believes," "plans," "anticip ...

Company Overview - Qiagen NV is a Netherlands-based holding company that provides "Sample to Insight" solutions, transforming biological samples into molecular insights through integrated sample and assay technologies, bioinformatics, and automation systems [1] - The company specializes in isolating and preparing DNA, RNA, and proteins from various biological materials, and its assay technologies enable the analysis of these biomolecules [1] - Qiagen operates primarily in two end markets: Molecular Diagnostics and Life Sciences, generating approximately 90% of its sales from recurring consumables revenue [4] Investment Context - Fivespan Partners has established a position in Qiagen and is engaging with its management to explore potential improvements [3][7] - Qiagen has struggled to create shareholder value post-Covid, with 1-, 3-, and 5-year returns of 1%, -6%, and 1%, respectively, while trading at around 13 times EV/EBITDA compared to peers at approximately 15 times [5] - The company has a strong market position and brand reputation but has lost focus on its core business, leading to missed opportunities for growth [6] Strategic Opportunities - Management is encouraged to invest more in its core business, improve communication with the market, and optimize its balance sheet to enhance shareholder value [6] - Qiagen's operating margin is currently at 25%, with potential for expansion to over 30% through a more disciplined approach [6] - The company holds $1.15 billion in cash and short-term investments against $1.39 billion in debt, suggesting room for leveraging to fund growth initiatives and share buybacks [6] Market Dynamics - Qiagen's dual-listing and geographical revenue distribution show that 52% of its FY24 sales are from North America, 32% from Europe, the Middle East, and Africa, and 16% from Asia [4] - The company has previously engaged in discussions for potential transactions, including a failed offer from Thermo Fisher Scientific at 43 euros per share, indicating its attractiveness as an acquisition target [8] - Fivespan's investment philosophy includes evaluating strategic transactions, and while it does not prioritize sales, it remains open to advocating for shareholder value in the event of acquisition offers [8]

Core Insights - Avantor, Inc. is a leading global provider of mission-critical products and services in the life sciences and advanced technology sectors [3] - The company will have its President and CEO, Michael Stubblefield, participate in a fireside chat at the Bank of America Securities 2025 Health Care Conference on May 13, 2025 [1] Company Overview - Avantor operates in over 300,000 customer locations across 180 countries, supporting critical research, development, and production activities [3] - The company focuses on enabling breakthroughs in medicine, healthcare, and technology through its comprehensive portfolio of life science tools [3] Event Details - The fireside chat will take place at approximately 10:00 a.m. Pacific Time [1] - A live audio webcast of the session will be available on Avantor's investor relations website, with a replay accessible for 30 days [2]

Core Viewpoint - Illinois Tool Works (ITW) exceeded earnings expectations for the quarter but faces challenges from tariffs and macroeconomic conditions, leading to a decline in share price [1][2]. Financial Performance - ITW reported earnings of $2.44 per share on sales of $3.8 billion, surpassing the consensus estimate of $2.35 per share but falling short of revenue expectations by approximately $40 million [2]. - Year-over-year sales decreased by 3.4%, attributed to foreign currency fluctuations and weak demand in certain markets [2]. Operational Insights - The company achieved an operating margin of 24.8% for the quarter, down from 26.8% for the full year 2024 [3]. - CEO Christopher A. O'Herlihy acknowledged the "uncertain external environment" but maintained the company's full-year guidance, expecting price increases and other measures to mitigate tariff impacts [3]. Market Position and Strategy - ITW's ability to pass on some tariff-related costs to customers is supported by its essential product offerings [4]. - The company manufactures a significant portion of its products in the markets where they are sold, which provides some insulation from tariffs, although it still depends on imports for raw materials [4]. Investment Considerations - Despite being in a challenging environment, ITW's stock has only declined by 7% year-to-date, suggesting potential for long-term investors [5]. - The company offers a nearly 3% dividend yield, making it an attractive option for patient investors [5].

Lincoln Electric Holdings (LECO) came out with quarterly earnings of $2.16 per share, missing the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.70%. A quarter ago, it was expected that this manufacturer of specialized welding products and other equipment would post earnings of $2 per share when it actually produced earnings of $2.57, deliverin ...

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

Company Performance - Stanley Black & Decker reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.68 per share, and up from $0.56 per share a year ago, representing an earnings surprise of 10.29% [1] - The company posted revenues of $3.74 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.37%, although this is a decline from year-ago revenues of $3.87 billion [2] - Over the last four quarters, Stanley Black & Decker has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Stanley Black & Decker shares have declined approximately 23.7% since the beginning of the year, compared to a decline of 5.5% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $1 on revenues of $4.02 billion, and for the current fiscal year, it is $5.14 on revenues of $15.3 billion [7] Industry Outlook - The Manufacturing - Tools & Related Products industry, to which Stanley Black & Decker belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Stanley Black & Decker's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than a factor of 2 to 1 [8]

NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to allegations of false and misleading statements regarding its financial reporting and revenue recognition practices during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Maravai securities between August 7, 2024, and February 24, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting, particularly concerning revenue recognition [3]. - It is alleged that Maravai improperly recognized approximately $3.9 million in revenue during fiscal year 2024 due to an error in recording revenue [4]. - The company is also accused of overstating its goodwill related to its acquisition of Alphazyme LLC [3][4]. Group 3: Impact on Stock Price - Following the announcement of the postponement of its fiscal 2024 earnings release and the need for additional time to complete its financial close, Maravai's stock price fell by nearly 22% [4].

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=14 ...